RU2010113981A - Применение гексапептидного антагониста рецептора тромбоцитарного фибриногена и альфа-эндорфина в качестве терапевтических средств - Google Patents
Применение гексапептидного антагониста рецептора тромбоцитарного фибриногена и альфа-эндорфина в качестве терапевтических средств Download PDFInfo
- Publication number
- RU2010113981A RU2010113981A RU2010113981/15A RU2010113981A RU2010113981A RU 2010113981 A RU2010113981 A RU 2010113981A RU 2010113981/15 A RU2010113981/15 A RU 2010113981/15A RU 2010113981 A RU2010113981 A RU 2010113981A RU 2010113981 A RU2010113981 A RU 2010113981A
- Authority
- RU
- Russia
- Prior art keywords
- diseases
- disease
- gly
- ser
- vascular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Abstract
1. Сочетание пептидов Pro-Ser-Hyp-Gly-Asp-Trp-OH и Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-OH или их солей или гидратов. ! 2. Сочетание по п.1, где пептиды содержатся в сочетании в количестве от 30 мас.% к 70 мас.% до 70 мас.% к 30 мас.%. ! 3. Сочетание по п.1 для применения в медицине. ! 4. Применение пептида Pro-Ser-Hyp-Gly-Asp-Trp-OH или сочетания по п.1, или 2, или 3 для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ. ! 5. Применение пептида по п.4, где злокачественная опухоль, аутоиммунное заболевание, фиброз, воспалительное заболевание, нейродегенеративное заболевание, инфекционное заболевание, заболевание легких, заболевание сердца и сосудов или болезнь обмена веществ выбраны из васкулита и избыточного ангиогенеза при аутоиммунных заболеваниях, системного склероза, рассеянного склероза, синдрома Шегрена, деформаций сосудов в сетях кровеносных и лимфатических сосудов, синдрома ДиДжорджа, врожденной геморрагической телеангиэктазии, пещеристой гемангиомы, кожной гемангиомы, деформаций лимфатических сосудов, артериопатии трансплантата, атеросклероза, анастомозов сосудов, жировой ткани при ожирении, хронического отторжения аллотрансплантата, болезней кожи, псориаза, папиллом, аллергического дерматита, келоидного рубца, пиогенных гранулем, нарывной болезни, саркомы Капоши у пациентов со СПИД, системного склероза, глазных болезней, стойкого гиперпластического синдрома стекловидного тела, диабетической р�
Claims (12)
1. Сочетание пептидов Pro-Ser-Hyp-Gly-Asp-Trp-OH и Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-OH или их солей или гидратов.
2. Сочетание по п.1, где пептиды содержатся в сочетании в количестве от 30 мас.% к 70 мас.% до 70 мас.% к 30 мас.%.
3. Сочетание по п.1 для применения в медицине.
4. Применение пептида Pro-Ser-Hyp-Gly-Asp-Trp-OH или сочетания по п.1, или 2, или 3 для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ.
5. Применение пептида по п.4, где злокачественная опухоль, аутоиммунное заболевание, фиброз, воспалительное заболевание, нейродегенеративное заболевание, инфекционное заболевание, заболевание легких, заболевание сердца и сосудов или болезнь обмена веществ выбраны из васкулита и избыточного ангиогенеза при аутоиммунных заболеваниях, системного склероза, рассеянного склероза, синдрома Шегрена, деформаций сосудов в сетях кровеносных и лимфатических сосудов, синдрома ДиДжорджа, врожденной геморрагической телеангиэктазии, пещеристой гемангиомы, кожной гемангиомы, деформаций лимфатических сосудов, артериопатии трансплантата, атеросклероза, анастомозов сосудов, жировой ткани при ожирении, хронического отторжения аллотрансплантата, болезней кожи, псориаза, папиллом, аллергического дерматита, келоидного рубца, пиогенных гранулем, нарывной болезни, саркомы Капоши у пациентов со СПИД, системного склероза, глазных болезней, стойкого гиперпластического синдрома стекловидного тела, диабетической ретинопатии, ретинопатии недоношенных, неоваскуляризации сосудистой оболочки глаза, заболеваний легких, легочной гипертензии, астмы, носовых полипов, ринита, хронического воспаления и обструкции дыхательных путей (COPD), кистозного фиброза, острого повреждения легких, формирующего пневмонию облитерирующего бронхиолита, заболеваний желудочно-кишечного тракта, воспалительного заболевания кишечника, пародонтоза, асцитов, перитонеальных спаек, циррозов печени, заболеваний репродуктивной системы, эндометриоза, маточного кровотечения, кист яичника, гиперстимуляции яичников, заболеваний костей и суставов, артрита и синовита, остеомиелита, формирования костного нароста, индуцированного ВИЧ ангиогенеза в костном мозге, заболеваний почек, ранней диабетической нефропатии.
6. Применение пептида Pro-Ser-Hyp-Gly-Asp-Trp-OH для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
7. Применение пептида Pro-Ser-Hyp-Gly-Asp-Trp-OH для получения лиофилизированного состава или буферного жидкого состава.
8. Фармацевтическая композиция, содержащая сочетание по п.1 совместно с по меньшей мере одним фармацевтически приемлемым носителем, криопротектором, лиопротектором, эксципиентом и/или разбавителем.
9. Фармацевтическая композиция по п.8 в форме лиофилизата или жидкого буферного раствора.
10. Фармацевтическая композиция по п.8 или 9, пригодная для внутривенного введения, перорального введения или для введения посредством ингаляции.
11. Фармацевтическая композиция по п.8 или 9 в форме состава искусственного материнского молока или заменителя материнского молока, пригодная для пероральной доставки новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
12. Фармацевтическая композиция по п.8 или 9, пригодная для лечения и/или профилактики злокачественной опухоли, аутоиммунного заболевания, фиброза, воспалительного заболевания, нейродегенеративного заболевания, инфекционного заболевания, заболевания легких, заболевания сердца и сосудов или болезни обмена веществ.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07017748 | 2007-09-11 | ||
EP07017748.0 | 2007-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2010113981A true RU2010113981A (ru) | 2011-10-20 |
Family
ID=40225088
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010113966/15A RU2010113966A (ru) | 2007-09-11 | 2008-09-09 | Применение меланотропинстимулирующего фактора в качестве терапевтического средства |
RU2010113977/15A RU2010113977A (ru) | 2007-09-11 | 2008-09-09 | Применение антагониста рецептора фибриногена и/или пептид фолликулярного гонадолиберина в качестве терапевтического средства при лечении инфекции streptococcus pneumoniae |
RU2010114047/15A RU2010114047A (ru) | 2007-09-11 | 2008-09-09 | Применение нейропептида af человека в качестве терапевтического средства |
RU2010114025/15A RU2010114025A (ru) | 2007-09-11 | 2008-09-09 | ПРИМЕНЕНИЕ ПЕПТИДА Gly-Arg-Gly-Asp-Asn-Pro В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА |
RU2010113995/15A RU2010113995A (ru) | 2007-09-11 | 2008-09-09 | Применение ацетил-(ala10,11)-rantes(1-14) и/или кальцитонина в качестве антиангиогенных средств |
RU2010113981/15A RU2010113981A (ru) | 2007-09-11 | 2008-09-09 | Применение гексапептидного антагониста рецептора тромбоцитарного фибриногена и альфа-эндорфина в качестве терапевтических средств |
RU2010114027/15A RU2010114027A (ru) | 2007-09-11 | 2008-09-09 | Большой гастрин i в качестве терапевтического средства |
RU2010114000/15A RU2010114000A (ru) | 2007-09-11 | 2008-09-09 | Применение нейропептида sf индивидуально или в сочетании с glp-2 в качестве терапевтического средства |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010113966/15A RU2010113966A (ru) | 2007-09-11 | 2008-09-09 | Применение меланотропинстимулирующего фактора в качестве терапевтического средства |
RU2010113977/15A RU2010113977A (ru) | 2007-09-11 | 2008-09-09 | Применение антагониста рецептора фибриногена и/или пептид фолликулярного гонадолиберина в качестве терапевтического средства при лечении инфекции streptococcus pneumoniae |
RU2010114047/15A RU2010114047A (ru) | 2007-09-11 | 2008-09-09 | Применение нейропептида af человека в качестве терапевтического средства |
RU2010114025/15A RU2010114025A (ru) | 2007-09-11 | 2008-09-09 | ПРИМЕНЕНИЕ ПЕПТИДА Gly-Arg-Gly-Asp-Asn-Pro В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА |
RU2010113995/15A RU2010113995A (ru) | 2007-09-11 | 2008-09-09 | Применение ацетил-(ala10,11)-rantes(1-14) и/или кальцитонина в качестве антиангиогенных средств |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010114027/15A RU2010114027A (ru) | 2007-09-11 | 2008-09-09 | Большой гастрин i в качестве терапевтического средства |
RU2010114000/15A RU2010114000A (ru) | 2007-09-11 | 2008-09-09 | Применение нейропептида sf индивидуально или в сочетании с glp-2 в качестве терапевтического средства |
Country Status (8)
Country | Link |
---|---|
US (8) | US20100204115A1 (ru) |
EP (8) | EP2187925A1 (ru) |
JP (8) | JP5385282B2 (ru) |
KR (8) | KR20100057058A (ru) |
AU (8) | AU2008297899A1 (ru) |
CA (8) | CA2698978A1 (ru) |
RU (8) | RU2010113966A (ru) |
WO (20) | WO2009033725A1 (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111647043A (zh) * | 2019-08-07 | 2020-09-11 | 中国农业大学 | 含有Hyp-Gly序列的一类抗血小板和抗血栓功能的寡肽 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2259768B1 (en) * | 2008-04-08 | 2019-05-22 | Merck Patent GmbH | Compositions containing cyclic peptides and methods of use |
MX2012006450A (es) * | 2009-12-10 | 2012-06-28 | Merck Patent Gmbh | Composicion farmaceutica que comprende oligopeptidos. |
JP5735634B2 (ja) * | 2010-04-23 | 2015-06-17 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | スフィンゴシン−1−リン酸受容体1アゴニストとしての4−(5−イソオキサゾリルまたは5−ピラゾリル−1,2,4−オキサジアゾール−3−イル)−マンデル酸アミド化合物 |
GB201020032D0 (en) * | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
US10478501B2 (en) | 2011-06-09 | 2019-11-19 | Merck Patent Gmbh | Method of treating disorders using a pharmaceutical composition of oligopeptides |
CN107496899A (zh) | 2011-09-29 | 2017-12-22 | 梅约医学教育与研究基金会 | 芳族阳离子肽和使用它们的方法 |
WO2014021942A1 (en) * | 2012-08-01 | 2014-02-06 | University Of Southern California | Methods for limiting development of neurodegeneration |
US9670259B2 (en) * | 2013-03-14 | 2017-06-06 | University Of Rochester | Method of inhibiting angiogenesis using inhibitors of G-protein-coupled receptor kinase interacting protein-1 (GIT1) |
EP2941091B1 (en) | 2014-04-30 | 2019-04-24 | Electrolux Appliances Aktiebolag | Hob with free configurable heating array and touchscreen control, method for operating a hob with free configurable heating array and touchscreen control and computer program product |
RU2577135C2 (ru) * | 2014-07-01 | 2016-03-10 | Диамондзлите Лимитед | Способ лечения пациентов с онкологическими заболеваниями кожи при развитии неопластических процессов кожной ткани, таких как меланома, базально-клеточный, плоскоклеточный рак (варианты) |
CN104888198A (zh) * | 2015-04-21 | 2015-09-09 | 徐志强 | 降钙素在制造延缓脑老化药物的新用途 |
KR20180033232A (ko) * | 2015-07-24 | 2018-04-02 | 온코트랙커 인코포레이티드 | 면역계 기능장애의 치료를 위한 감마 세크레타제 조절제 |
IL268349B1 (en) | 2017-02-17 | 2024-04-01 | Hutchinson Fred Cancer Res | Combination therapies for the treatment of BCMA-associated cancer and autoimmune disorders |
CN108395470B (zh) * | 2018-01-10 | 2020-10-09 | 北京工业大学 | 具有抑制登革病毒复制作用的短肽及其应用 |
JP6709440B2 (ja) * | 2018-06-08 | 2020-06-17 | 学校法人福岡大学 | 肥厚性瘢痕の形成抑制用組成物 |
WO2023072485A1 (en) * | 2021-10-25 | 2023-05-04 | Pharma Holdings As | Modified tripeptides for use in the treatment of a non-enveloped virus infection |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4097471A (en) * | 1977-05-26 | 1978-06-27 | American Home Products Corporation | Polypeptides with morphine-like activity |
EP0076676B1 (en) * | 1981-10-05 | 1986-12-30 | Tni Pharmaceuticals, Inc. | Process for using endorphins as antitumour agents |
JPS6023086B2 (ja) * | 1982-09-04 | 1985-06-05 | 工業技術院長 | アンジオテンシン転換酵素阻害剤 |
US4474753A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Topical drug delivery system utilizing thermosetting gels |
US4478822A (en) | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
JPS62270533A (ja) * | 1986-05-20 | 1987-11-24 | Agency Of Ind Science & Technol | 経口摂食物 |
CA1324954C (en) * | 1988-03-10 | 1993-12-07 | Erkki I. Ruoslahti | Inhibition of cell migration with synthetic peptides |
US5843156A (en) * | 1988-08-24 | 1998-12-01 | Endoluminal Therapeutics, Inc. | Local polymeric gel cellular therapy |
JPH02240020A (ja) * | 1989-01-26 | 1990-09-25 | Childrens Medical Center Corp:The | 外科的切除後の腫瘍再発阻止剤 |
US5538739A (en) * | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
US5256396A (en) | 1990-01-24 | 1993-10-26 | Colgate-Palmolive Company | Topical composition |
US6017877A (en) * | 1990-04-06 | 2000-01-25 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
JP2745351B2 (ja) * | 1991-02-14 | 1998-04-28 | 富士写真フイルム株式会社 | ペプチド誘導体及びその用途 |
EP0527283B1 (en) | 1991-08-12 | 1997-11-26 | Societe Des Produits Nestle S.A. | Food composition |
EP0667783B1 (en) * | 1991-11-07 | 1999-04-21 | The University Of Southern California | Compositions and methods for preventing adhesion formation |
JP2918746B2 (ja) * | 1991-12-18 | 1999-07-12 | 富士写真フイルム株式会社 | ペプチド誘導体およびその用途 |
MX9301789A (es) * | 1992-04-03 | 1993-10-01 | Iaf Biochem Int | Nuevos oligopeptidos lipofilicos con actividad inmunomoduladora. |
US5817628A (en) * | 1992-12-02 | 1998-10-06 | The Rockefeller University | Dynorphin a suppression of natural killer cell activity |
US5591719A (en) * | 1992-12-10 | 1997-01-07 | Regents Of The University Of Minnesota | Method for treating acute and chronic inflammatory disorders using polypeptides with fibronectin activity |
WO1994013692A1 (en) * | 1992-12-10 | 1994-06-23 | Regents Of The University Of Minnesota | Polypeptides useful for treating inflammatory disorders |
WO1994017097A1 (en) * | 1993-01-19 | 1994-08-04 | Regents Of The University Of Minnesota | Synthetic fibronectin fragments as inhibitors of retroviral infections |
CA2172493C (en) * | 1993-09-24 | 2003-09-16 | Kathleen Elizabeth Rodgers | Use of angiotensin iii and analogs thereof in tissue repair |
JP3581174B2 (ja) * | 1993-09-30 | 2004-10-27 | 新日本製鐵株式会社 | 新規ペプチド並びにそれを用いた血小板凝集抑制剤、体外循環用血液凝固抑制剤及び輸血用血小板製剤保護剤 |
AU673466B2 (en) * | 1993-09-30 | 1996-11-07 | Nippon Steel Corporation | Novel peptide, active as inhibitors of platelet aggregation |
US5770565A (en) * | 1994-04-13 | 1998-06-23 | La Jolla Cancer Research Center | Peptides for reducing or inhibiting bone resorption |
CN1096862C (zh) | 1994-05-06 | 2002-12-25 | 辉瑞大药厂 | 阿齐霉素的控释剂型 |
DE19529909C2 (de) * | 1995-08-15 | 1998-04-09 | Fresenius Ag | Wässrige Spüllösung |
US5691314A (en) * | 1996-03-18 | 1997-11-25 | The Medical College Of Hampton Roads | Adjunctive therapy |
AU3499997A (en) * | 1996-06-24 | 1998-01-14 | Rockefeller University, The | Method of using ligands of the kappa opioid receptor |
TW360501B (en) | 1996-06-27 | 1999-06-11 | Nestle Sa | Dietetically balanced milk product |
AU3215597A (en) * | 1996-08-30 | 1998-03-19 | Biomeasure Incorporated | Method of inhibiting fibrosis with a somatostatin agonist |
ATE193636T1 (de) | 1996-09-24 | 2000-06-15 | Nestle Sa | Milchaustauschprodukt und verfahren zu dessen herstellung |
GB9704174D0 (en) * | 1997-02-28 | 1997-04-16 | Univ Birmingham | Agent for medical treatment |
WO1999003491A1 (en) * | 1997-07-15 | 1999-01-28 | Novo Nordisk A/S | New use of nociceptin |
IT1299134B1 (it) * | 1998-02-02 | 2000-02-29 | Angeletti P Ist Richerche Bio | Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi |
US6239109B1 (en) * | 1998-02-09 | 2001-05-29 | University Of Southern California | Method of promoting erythropoiesis |
US5958874A (en) * | 1998-02-18 | 1999-09-28 | The Research Foundation Of State University Of New York | Recombinant fibronectin-based extracellular matrix for wound healing |
BR9915573B1 (pt) | 1998-11-24 | 2010-11-30 | processo de preparação de uma formulação infantil predominantemente a base de uma matéria-prima de leite oriunda de soro do leite, em que a composição em aminoácidos é semelhante àquela do leite humano. | |
WO2001017958A2 (en) * | 1999-09-10 | 2001-03-15 | Merck & Co., Inc. | Neuropeptide sf receptor assays, compounds and therapeutic methods |
US6759520B1 (en) * | 1999-10-28 | 2004-07-06 | The New England Medical Center Hospitals, Inc. | Chimeric analgesic peptides |
US20020103131A1 (en) * | 2001-01-26 | 2002-08-01 | Jacobson Jill D. | Prevention of diabetes by administration of GnRH antagonists |
RU2319501C2 (ru) * | 2001-04-30 | 2008-03-20 | Центарис Гмбх | Способ лечения болезни альцгеймера |
DE60216458T2 (de) * | 2001-05-16 | 2007-09-27 | Nicholas P. Wilmette Plotnikoff | Verfahren zum auslösen einer anhaltenden immunreaktion |
DE10137174A1 (de) * | 2001-07-31 | 2003-02-13 | Zentaris Ag | Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität |
ES2287065T3 (es) | 2001-11-23 | 2007-12-16 | Societe Des Produits Nestle S.A. | Proceso para la preparacion de leche en polvo y productos lacteos concentrados. |
EP1531846A4 (en) * | 2002-02-27 | 2006-04-19 | Us Gov Health & Human Serv | CONJUGATES OF LIGAND, LINK AND CYTOTOXIC AGENS, AND RELATED COMPOSITIONS AND USE PROCESSES |
GB0208499D0 (en) * | 2002-04-12 | 2002-05-22 | Microscience Ltd | Streptococcal genes |
AU2003276828A1 (en) * | 2002-05-10 | 2004-03-11 | Children's Medical Center Corporation | Minicell display and products therefrom |
WO2004043396A2 (en) * | 2002-11-09 | 2004-05-27 | Nobex Corporation | Modified carbamate-containing prodrugs and methods of synthesizing same |
US20050282747A1 (en) * | 2003-10-01 | 2005-12-22 | The Research Foundation Of State University Of New York At Stony Brook | Methods and compositions for wound healing |
CA2511711A1 (en) * | 2004-07-08 | 2006-01-08 | Les Laboratoires Omega Ltee | Liquid pharmaceutical formulations of octreotide, manufacturing process and container for the same |
AU2005319578A1 (en) * | 2004-11-24 | 2006-06-29 | Neopro Labs, Llc | Methods and compositions for treating conditions |
US7550150B2 (en) * | 2005-03-15 | 2009-06-23 | Barros Research Institute | Methods of treating or preventing a disease, disorder or condition associated with a viral infection |
EP1885391A1 (en) * | 2005-05-19 | 2008-02-13 | Novo Nordisk A/S | Use of glp-2 for the treatment of ischemia-reperfusion injury |
JP2009506076A (ja) * | 2005-08-26 | 2009-02-12 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ | 三叉神経疼痛のための薬物送達のための治療手順 |
JP2009510134A (ja) * | 2005-10-07 | 2009-03-12 | ワラタ ファーマシューティカルズ, インコーポレイテッド | Dpp−iv阻害剤およびガストリン化合物の組み合わせ使用 |
WO2007095737A1 (en) * | 2006-02-21 | 2007-08-30 | Waratah Pharmaceuticals Inc. | Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound |
WO2007100335A1 (en) * | 2006-03-03 | 2007-09-07 | The Mclean Hospital Corporation | Methods for the treatment of mood disorders |
DK1993515T3 (da) | 2006-03-10 | 2009-12-07 | Laboswiss Ag | Fremgangsmåde til solubilisering, dispergering og stabilisering af stoffer, produkter, der er fremstillet efter fremgangsmåden og anvendelsen af samme |
US20080161324A1 (en) * | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
JP2010521495A (ja) * | 2007-03-14 | 2010-06-24 | アーチ セラピューティクス, インコーポレイテッド | 漏出性または損傷を受けたタイトジャンクションの処置および細胞外マトリクスの増強 |
-
2008
- 2008-09-09 WO PCT/EP2008/007653 patent/WO2009033725A1/en active Application Filing
- 2008-09-09 JP JP2010523392A patent/JP5385282B2/ja not_active Expired - Fee Related
- 2008-09-09 RU RU2010113966/15A patent/RU2010113966A/ru not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007715 patent/WO2009040021A2/en active Application Filing
- 2008-09-09 US US12/677,544 patent/US20100204115A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/008131 patent/WO2009033803A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007479 patent/WO2009033681A2/en active Application Filing
- 2008-09-09 KR KR1020107005641A patent/KR20100057058A/ko not_active Application Discontinuation
- 2008-09-09 EP EP08830659A patent/EP2187925A1/en not_active Withdrawn
- 2008-09-09 WO PCT/EP2008/007545 patent/WO2009039995A1/en active Application Filing
- 2008-09-09 CA CA2698978A patent/CA2698978A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007853 patent/WO2009049742A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007639 patent/WO2009043459A1/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007667 patent/WO2009033730A2/en active Application Filing
- 2008-09-09 EP EP08802184A patent/EP2187952A1/en not_active Withdrawn
- 2008-09-09 CA CA2699054A patent/CA2699054A1/en not_active Abandoned
- 2008-09-09 US US12/677,289 patent/US20100210532A1/en not_active Abandoned
- 2008-09-09 CA CA2698775A patent/CA2698775A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007965 patent/WO2009033781A2/en active Application Filing
- 2008-09-09 CA CA2699049A patent/CA2699049A1/en not_active Abandoned
- 2008-09-09 CA CA2699075A patent/CA2699075A1/en not_active Abandoned
- 2008-09-09 EP EP08840110A patent/EP2205262A2/en not_active Withdrawn
- 2008-09-09 CA CA2699244A patent/CA2699244A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/008010 patent/WO2009046857A1/en active Application Filing
- 2008-09-09 AU AU2008297899A patent/AU2008297899A1/en not_active Abandoned
- 2008-09-09 AU AU2008306264A patent/AU2008306264A1/en not_active Abandoned
- 2008-09-09 US US12/677,107 patent/US20100190711A1/en not_active Abandoned
- 2008-09-09 EP EP08785860A patent/EP2187908A1/en not_active Withdrawn
- 2008-09-09 WO PCT/EP2008/007809 patent/WO2009040049A2/en active Application Filing
- 2008-09-09 JP JP2010523396A patent/JP2010539023A/ja active Pending
- 2008-09-09 AU AU2008303811A patent/AU2008303811A1/en not_active Abandoned
- 2008-09-09 US US12/677,585 patent/US20100197608A1/en not_active Abandoned
- 2008-09-09 RU RU2010113977/15A patent/RU2010113977A/ru not_active Application Discontinuation
- 2008-09-09 EP EP08802100A patent/EP2185180A1/en not_active Withdrawn
- 2008-09-09 WO PCT/EP2008/007516 patent/WO2009039974A2/en active Application Filing
- 2008-09-09 KR KR1020107005593A patent/KR20100058549A/ko not_active Application Discontinuation
- 2008-09-09 US US12/676,947 patent/US20100184704A1/en not_active Abandoned
- 2008-09-09 AU AU2008303957A patent/AU2008303957A1/en not_active Abandoned
- 2008-09-09 US US12/677,449 patent/US20100190716A1/en not_active Abandoned
- 2008-09-09 JP JP2010523377A patent/JP2010539004A/ja active Pending
- 2008-09-09 CA CA2699177A patent/CA2699177A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007874 patent/WO2009033765A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007537 patent/WO2009039989A1/en active Application Filing
- 2008-09-09 KR KR1020107005621A patent/KR20100057053A/ko not_active Application Discontinuation
- 2008-09-09 RU RU2010114047/15A patent/RU2010114047A/ru not_active Application Discontinuation
- 2008-09-09 RU RU2010114025/15A patent/RU2010114025A/ru not_active Application Discontinuation
- 2008-09-09 EP EP08802095A patent/EP2187906A2/en not_active Withdrawn
- 2008-09-09 US US12/677,305 patent/US20100204130A1/en not_active Abandoned
- 2008-09-09 RU RU2010113995/15A patent/RU2010113995A/ru not_active Application Discontinuation
- 2008-09-09 KR KR1020107005649A patent/KR20100061678A/ko not_active Application Discontinuation
- 2008-09-09 AU AU2008303951A patent/AU2008303951A1/en not_active Abandoned
- 2008-09-09 KR KR1020107005633A patent/KR20100061483A/ko not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/008129 patent/WO2009033801A2/en active Application Filing
- 2008-09-09 EP EP08802332A patent/EP2187923A2/en not_active Withdrawn
- 2008-09-09 RU RU2010113981/15A patent/RU2010113981A/ru not_active Application Discontinuation
- 2008-09-09 JP JP2010523370A patent/JP2010538997A/ja active Pending
- 2008-09-09 JP JP2010523413A patent/JP2010539040A/ja active Pending
- 2008-09-09 RU RU2010114027/15A patent/RU2010114027A/ru not_active Application Discontinuation
- 2008-09-09 AU AU2008303889A patent/AU2008303889A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007720 patent/WO2009040025A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007536 patent/WO2009039988A2/en active Application Filing
- 2008-09-09 US US12/676,909 patent/US20100197601A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007942 patent/WO2009040071A2/en active Application Filing
- 2008-09-09 AU AU2008314244A patent/AU2008314244A1/en not_active Abandoned
- 2008-09-09 RU RU2010114000/15A patent/RU2010114000A/ru not_active Application Discontinuation
- 2008-09-09 KR KR1020107005599A patent/KR20100056511A/ko not_active Application Discontinuation
- 2008-09-09 EP EP08802250A patent/EP2187917A2/en not_active Withdrawn
- 2008-09-09 CA CA2699107A patent/CA2699107A1/en not_active Abandoned
- 2008-09-09 AU AU2008303950A patent/AU2008303950A1/en not_active Abandoned
- 2008-09-09 JP JP2010523417A patent/JP2010539044A/ja active Pending
- 2008-09-09 JP JP2010523407A patent/JP2010539034A/ja active Pending
- 2008-09-09 JP JP2010523371A patent/JP2010538998A/ja active Pending
- 2008-09-09 WO PCT/EP2008/007434 patent/WO2009033659A1/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007608 patent/WO2009043441A1/en active Application Filing
- 2008-09-09 KR KR1020107005611A patent/KR20100058553A/ko not_active Application Discontinuation
- 2008-09-09 KR KR1020107005585A patent/KR20100059855A/ko not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111647043A (zh) * | 2019-08-07 | 2020-09-11 | 中国农业大学 | 含有Hyp-Gly序列的一类抗血小板和抗血栓功能的寡肽 |
CN111647043B (zh) * | 2019-08-07 | 2022-03-22 | 中国农业大学 | 含有Hyp-Gly序列的一类抗血小板和抗血栓功能的寡肽 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2010113981A (ru) | Применение гексапептидного антагониста рецептора тромбоцитарного фибриногена и альфа-эндорфина в качестве терапевтических средств | |
RU2010114058A (ru) | Применение пептида в качестве терапевтического средства | |
RU2010114029A (ru) | Астрессин и бета-эндорфин для применения в качестве терапевтических средств | |
RU2010113991A (ru) | Применение пептида галанина в качестве терапевтического средства | |
RU2010114048A (ru) | Применение пептида дефензина в качестве терапевтического средства | |
RU2010113990A (ru) | Применение пептида ламинина в качестве терапевтического средства | |
RU2010113967A (ru) | Применение родственного стресскопину пептида в качестве терапевтического средства | |
RU2010114004A (ru) | Применение меланиноконцентрирующего гормона и met-энкефалина в качестве терапевтических средств | |
RU2010114026A (ru) | Применение глютенэкзорфина с в качестве терапевтического средства | |
RU2010114006A (ru) | Применение пептида в качестве терапевтического средства | |
RU2010114059A (ru) | Применение фибронектинового фрагмента (196-203) в качестве терапевтического средства | |
RU2010114038A (ru) | Применение адреномедуллина в качестве терапевтического средства для лечения избыточного ангиогенеза | |
RU2010113996A (ru) | Применение кальцитонина в качестве антиангиогенного средства | |
JP2010155842A5 (ru) | ||
RU2010114033A (ru) | Применение ингибитора nf-каппа в sn50 и необязательно ангиотензина iii в качестве терапевтических средств при лечении, например, инфекции hbv | |
RU2010113979A (ru) | Применение bubuc и необязательно eaa-marti (26-35) в качестве терапевтического средства для лечения инфекций hcmv | |
JP2013537172A (ja) | 血管新生阻害剤の気道投与 | |
RU2010114054A (ru) | Применение пептида в качестве терапевтического средства | |
JP6858305B2 (ja) | 関節リウマチを予防及び治療するための薬物の製造における選択性tnfr1拮抗ペプチドの使用 | |
RU2010114052A (ru) | Применение пептида в качестве терапевтического средства | |
TWI429451B (zh) | 對具有elr-cxc趨化素高度親和力的受體蛋白細胞所引發疾病之拮抗治療劑 | |
RU2010114008A (ru) | ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ ГАСТРИНА 1 И G-Pen-GRGDSPCA | |
RU2007105137A (ru) | Улучшенные варианты апротинина | |
RU2010114022A (ru) | Сочетание спленопентина и тимопентина и их применение в лекарственном средстве | |
AU2006273696B2 (en) | Airway administration of activated protein C in inflammatory conditions affecting the respiratory tract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20110912 |